Cover Image
Read Now

Anaplastic lymphoma kinase inhibitors for genetically rearranged non-small cell lung cancer a review of cost-effectiveness and guidelines

Despite the availability of direct and indirect evidence comparing the clinical effectiveness of different anaplastic lymphoma kinase inhibitors (ALKIs), comparative cost-effectiveness of these tyrosine kinase inhibitors (TKIs) is relatively less established, particularly in the first- and second-li...

Full description

Bibliographic Details
Main Authors: Islam, Saadul, Argáez, Charlene (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, November 30, 2018
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Canada
Treatment Outcome
Carcinoma, Non-small-cell Lung / Genetics
Guidelines As Topic
Anaplastic Lymphoma Kinase / Therapeutic Use
Carcinoma, Non-small-cell Lung / Drug Therapy
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02303nam a2200325 u 4500
001 EB001872167
003 EBX01000000000000001035538
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190824 r ||| eng
100 1 |a Islam, Saadul 
245 0 0 |a Anaplastic lymphoma kinase inhibitors for genetically rearranged non-small cell lung cancer  |h Elektronische Ressource  |b a review of cost-effectiveness and guidelines  |c Saadul Islam, Charlene Argaez 
250 |a Version 1.0 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2018, November 30, 2018 
300 |a 1 PDF file (27 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Canada 
653 |a Treatment Outcome 
653 |a Carcinoma, Non-Small-Cell Lung / genetics 
653 |a Guidelines as Topic 
653 |a Anaplastic Lymphoma Kinase / therapeutic use 
653 |a Carcinoma, Non-Small-Cell Lung / drug therapy 
700 1 |a Argáez, Charlene  |e [author] 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH rapid response report: summary with critical appraisal 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK538919  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a Despite the availability of direct and indirect evidence comparing the clinical effectiveness of different anaplastic lymphoma kinase inhibitors (ALKIs), comparative cost-effectiveness of these tyrosine kinase inhibitors (TKIs) is relatively less established, particularly in the first- and second-line settings. In addition, local and international jurisdictions can benefit from evidence-based guidelines outlining the sequence of ALKIs at different stages of cancer. This report was undertaken to examine the current evidence surrounding the comparative cost-effectiveness of first-line ALKIs among patients naive to previous anaplastic lymphoma kinase (ALK) treatment (ALK-naive) as well as second-line ALKIs among patients who have been pretreated with other ALKIs and had disease progression (ALKpretreated). Evidence-based guidelines informing the sequence of ALKIs in both settings were also investigated 

Similar Items